

REPLACED BY
ART 34 AMDT

CLAIMS

1. A purified subfragment, obtainable by means of a polymerase-based amplification process with reverse transcriptase RT-PCR, of an RNA sequence coding
5 for a neuroaminidase protein NAY derived from the genome of an avian influenza virus with epidemic subtype (HxNy).

2. A purified subfragment according to claim 1, in which said neuroaminidase protein NAY is represented
10 by NA1, and in which said reverse transcriptase RT-PCR polymerises a cDNA derived from said sequence, said cDNA being linked to the following two polynucleotide sequences: forward primer 5'- GCG CGC GGC CGC CAG GAG
TTT AAA ATG AAT CCA AAT C -3' and reverse primer 5'-
15 GCG CGC GGC CGC CTA CTT GTC AAT GGT GAA TGG C -3'.

3. A purified subfragment according to claim 1, which has a length of about 1.4 Kb.

4. A plasmid comprising the subfragment according to one or more of the preceding claims.

20 5. A process for expressing a neuroaminidase protein NAY, in particular for use as an antigenic marker for tests for the detection of anti-NAY antibodies induced by avian influenza viruses with epidemic subtype (HxNy), comprising a step of
25 expression in baculovirus vector of a cDNA coding for

REPLACED BY
ART 34 AMDT

said protein.

6. A process according to claim 5, comprising: -
a step of cloning of said baculovirus vector in E.coli
cells; - a step of infection of insect cells,
5 especially *Trichoplusia ni*, by means of said
baculovirus vector.

7. A process according to claim 5, in which said
step of expression in baculovirus vector occurs in an
expression system Bac-to-Bac®.

10 8. A process according to claim 5, in which said
neuroaminidase protein NAY to be expressed is derivable
from the subfragment of claim 1 or claim 2.

9. A process according to claim 8, in which said
subfragment is digested with a restriction enzyme NotI,
15 linked to a donor plasmid pFast-Bac cleaved with said
restriction enzyme NotI and cloned into competent
E.coli DH5α competent cells.

10. A process according to claim 9, in which
E.coli DH10Bac cells derived from said process and
20 containing said baculovirus plasmid are pFast-Bac-
transformed, said plasmid is isolated from said cells
and used for the transfection of *Trichoplusia ni* insect
cells.

11. A recombinant antigen obtainable by
25 expression in baculovirus vector of the subfragment of

REPLACED BY
ART 34 AMDT

claim 1 or claim 2.

12. A recombinant antigen according to claim 11, comprising a cellular carrier having artificially incorporated said recombinant baculovirus.

5 13. A recombinant antigen according to claim 11, comprising an insect cell carrier, especially *Trichoplusia ni*, infected with said recombinant baculovirus cloned in an *E.coli* bacterium.

10 14. A recombinant antigen according to any of claims 11 to 13, in which said subfragment can be expressed by means of the expression process of one or more of claims 5 to 10.

15 15. A recombinant antigen according to claim 11, in which said antigen consists of a purified protein obtained from said subfragment.

16. A recombinant antigen with at least one genomic sequence coding for a neuroaminidase protein NAY, for use in a test for the detection of anti-NAY antibodies induced by avian influenza virus with
20 specific epidemic strain (HxNy).

17. A recombinant antigen according to claim 16, in which said detection test is carried out on a biological fluid of animals selected from a group of animals at least a part of which have been subjected to
25 vaccination by means of a heterologous vaccine

characterized by the same subtype of viral haemoagglutinin Hax and a different subtype of neuroaminidase NAY.

18. A recombinant antigen according to claim 16
5 or 17, in which said genomic sequence is obtainable by expression in baculovirus of the subfragment of claim 1 or claim 2.

19. A recombinant antigen according to claim 16
or 17, in which said genomic sequence coding for a
10 neuroaminidase protein NAY can be expressed by means of the expression process of one or more of claims 5 to 10.

20. A diagnostic method for detecting the
positivity to an avian influenza virus infection with
15 specific epidemic strain (HxNy) comprising the steps of:

- preparing an antigen having at least one genomic sequence coding for a neuroaminidase protein (NAY);
- contacting said antigen with a specimen of
20 animal biological fluid to be tested;
- evidencing of an antigen-antibody reaction by means of a positivity detection test.

21. A diagnostic method according to claim 20, in which said test for the detection of positivity is an
25 immunofluorescence or immunoperoxidase test.

22. A diagnostic method according to claim 20, in which said test for the detection of positivity is an ELISA test.

23. A diagnostic method according to claim 20, in which said test for the detection of positivity is a colour test that is adapted to be carried out on the field by means of an inert support with said antigen adsorbed on.

24. A process for the vaccination against avian influenza virus infection with specific epidemic strain HxNy comprising the steps of:

- preparing a heterologous vaccine characterized by the same subtype of viral haemoagglutinin Hax and a different subtype of neuroaminidase Naz;

- administering said vaccine to at least one group of animals selected from a population at risk of infection;

- detecting the positivity to the virus infection of said avian influenza by:
 - preparing an antigen having at least one genomic sequence coding for a neuroaminidase protein (NAy); taking biological fluids from the body of the animals comprised in said animal population; contacting said antigen with said biological fluids, with subsequent evidencing of an antigen-antibody reaction by means of a positivity

REPLACED BY
ART 24

detection test.

25. A vaccination process according to claim 24,
in which said detection step is obtained by means of
the diagnostic method according to one or more of
5 claims 20 to 23.

26. A vaccination process according to claim 24,
in which said antigen is obtained according to one or
more of claims 11 to 15.

27. A vaccination process according to claim 24,
10 in which said vaccine is a natural vaccine obtained by
inactivating a natural virus.

28. A diagnostic kit for a test for detecting on
an animal population the positivity to an avian
influenza virus infection with epidemic subtype (HxNy),
15 comprising

- a solid support of an inert material;
- an antigen with at least a genomic sequence
coding for a neuroaminidase protein NAY in a state that
is substantially non modified as compared with that of
20 the specific avian influenza virus strain (HxNy), said
antigen being associated onto said solid support;

- a reagent that is adapted to colorimetrically
evidence the positivity to infection in the presence of
anti-NAY antibodies contained in a biological fluid of
25 an animal.

REPLACED BY
ART 34 AMDT

29. A diagnostic kit according to claim 28, in which said biological fluid is derived from a population of animals at risk of infection, at least one group thereof having been treated with a heterologous vaccine characterized by the same subtype of viral haemoagglutinin Hax and a different subtype of neuroaminidase Naz, said kit establishing in any case the discrimination of the infected individuals from the other individuals.

30. A diagnostic kit according to claim 28, in which said antigen is obtained in accordance with one or more of claims 11 to 15.

31. A diagnostic kit according to claim 28, in which said support is selected from the group comprising: latex spheres, plastic supports.